Share Your News Now

If you would like to share news or information with our readers, please send the unique stories, business news organization events, and school news to us includinig your name and phone number in case more information is needed.

For news and information consideration, please send to News@scdaily.com
or contact
John Robbins **832-280-5815**
Jun Gai **281-498-4310**

Southern DAILY
Make Today Different
Southern Daily News is published by Southern News Group Daily

Publisher: Wea H. Lee
President: Catherine Lee
Editor: John Robbins, Jun Gai
Address: 11122 Bellaire Blvd., Houston, TX 77072
E-mail: News@scdaily.com

Mr. Lee's Commentary and Dairy

Inside C2

Wednesday September 02, 2020 | www.today-america.com | Southern News Group

Trump visits Kenosha, not to comfort Blake family but back police

U.S. President Donald Trump talks to reporters as he stands with Kenosha police and business people while examining property damage to a business while visiting the city in the aftermath of recent protests against police brutality and racial injustice and ensuing violence after the shooting of Jacob Blake by a police officer in Kenosha, Wisconsin, U.S., September 1, 2020. REUTERS/Leah Millis

KENOSHA, Wis. (Reuters) - President Donald Trump defied requests to stay away and visited Kenosha, Wisconsin, on Tuesday, not to comfort the family of a Black man shot by a white police officer but to express support for law enforcement in a city rocked by civil unrest.

U.S. President Donald Trump talks to reporters as he stands with Kenosha police and business people while examining property damage to a business while visiting the city in the aftermath of recent protests against police brutality and racial injustice and ensuing violence after the shooting of Jacob Blake by a police officer in Kenosha, Wisconsin, U.S., September 1, 2020. REUTERS/Leah Millis

With the United States polarized over issues of racial injustice and police use of force, Trump is appealing to his base of white supporters with a "law and order" message as opinion polls show him cutting into the lead of his Democratic rival, former vice president Joe Biden.

The Republican president did not visit Blake, who was paralyzed from the waist down after a white police officer fired at his back seven times on Aug. 23, nor his family, but did plan to meet with his mother's pastor.

Instead he promised to rebuild Kenosha and provide more federal spending to Wisconsin, a political battleground state Trump won narrowly in 2016 and badly needs to keep in his column as he seeks re-election on Nov. 3.

RELATED COVERAGE
Trump promises $42 million to support public safety in Wisconsin

The president visited a burned-out furniture store that was destroyed in the upheaval and then a makeshift command center to praise National Guard troops who were called in to reinforce local police after several nights of peaceful protests gave way to looting, arson and gunfire.

"These are not acts of peaceful protest, but really domestic terror," Trump told a group of local business leaders in a high school gym, flanked by his Attorney General Bill Barr and Acting Secretary of Homeland Security Chad Wolf.

Peaceful demonstrators have complained that violent agitators, often white, have hijacked their protests with property damage. But many have also sharply criticized the police, saying the United States needs to completely rethink its law enforcement practices.

"To stop the political violence, we must also confront the radical ideology. ... We have to condemn the dangerous anti-police rhetoric," Trump said.

The president pledged to provide $1 million in federal support to Kenosha law enforcement, $4 million to small businesses, and $42 million to public safety statewide, contrasting that with leftist calls to "defund the police."

"I'm committed to helping Kenosha rebuild," Trump said.

The state's Democratic governor and the city's Democratic mayor both urged Trump to avoid Kenosha to prevent inflaming tensions and allow citizens to heal, but the president dismissed their appeals in order to show support for law enforcement and business owners whose stores were looted and set ablaze.

Trump has sought to blame Democrats, calling them soft on the violence and property damage that has broken out at anti-racism protests since George Floyd, a Black man, died on May 25 after a white police officer knelt on his neck.

The country was still reckoning with that case when a white officer in Kenosha fired seven shots at the back of Jacob Blake, 29, as he entered his car on Aug. 23.

Kenosha has become one of the flashpoint cities where anti-racist demonstrators have clashed with Trump supporters who have converged on protest sites, sometimes openly carrying arms while vowing to protect property from looters.

A 17-year-old Trump supporter has been charged with killing two people and wounding another with a semi-automatic rifle in Kenosha. Trump defended the white teenager, who faces six criminal counts, and declined to condemn violence from his supporters.

But in Portland, Oregon, site of three months of nightly protests that have often turned violent, a Trump supporter was shot dead on Saturday and the president lamented that "they executed a man in the street."

WEA LEE'S GLOBAL NOTES

09/01/2020 CORONAVIRUS DIARY

Only A Vaccine Can Rescue Us

When a coronavirus vaccine comes on the market, people will likely need two doses.

The federal government has given large amounts of money to six pharmaceutical companies as an incentive for them to speed up vaccine development and clinical trials and get their products to market in record time.

Two of these companies, Moderna and Pfizer, are now in Phase 3 of large clinical trials with 30,000 volunteers. The volunteers in each of the trials are getting two doses of the vaccine, with Moderna spacing their shots out 28 days apart and Pfizer spacing theirs out by 21 days. These trials are already moving at a good clip.

Johnson & Johnson are also already in Phase 3 of their clinical trials. Volunteers will take one or two doses in these trials.

We need to produce 600 million doses for the U.S. which is a very big task. Dr. Nada Sanders, a professor of supply chain management at Northeastern University said, "Doubling is a huge supply chain issue and you have to double everything in the supply chain."

Today we are still facing critical challenges all over the whole nation. A lot of people still do not believe in wearing facial masks, including the RNC. At the White House last Thursday 1,500 people attended the convention event and nobody was wearing a mask.

Let us all hope the vaccine will come on the market soon. That might be the only way we can save our lives.

SOUTHERN NEWS GROUP 40th ANNIVERSARY 1979-2019
STV KVVV15.3 美南國際電視網

Southern News Group Chairman / CEO
Chairman of International Trade & Culture Center
Chairman of International District Houston Texas


Publisher Southern Daily Wea H. Lee

Stay Home! **BUSINESS** *Wear Mask!*

COVID-19 Vaccines Currently Being Evaluated In Clinical Trials

Update: NIH-Moderna, Pfizer And AstraZeneca Investigational COVID-19 Vaccine Trials



Heavily infected with SARS-COV-2 virus particles (orange), isolated from a patient sample. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. (NIAID)

Compiled And Edited By John T. Robbins, Southern Daily Editor

The investigational vaccine known as mRNA-1273 protected mice from infection with SARS-CoV-2, the virus that causes COVID-19, according to research published today in Nature. Scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the **National Institutes of Health, and the biotechnology company Moderna, based in Cambridge, Massachusetts,** along with collaborators from the University of North Carolina at Chapel Hill, Vanderbilt University Medical Center in Nashville, and the **University of Texas at Austin** conducted the preclinical research. NIAID Vaccine Research Center (VRC) scientists worked with investigators from the University of Texas at Austin to identify the atomic structure of the spike protein on the surface of the novel coronavirus. This structure was used by VRC and Moderna in the development of the vaccine candidate.

The findings show that the investigational vaccine induced neutralizing antibodies in mice when given as two intramuscular injections of a 1-microgram (mcg) dose three weeks apart. Additional experiments found that mice given two injections of the 1-mcg dose and later challenged with SARS-CoV-2 virus either 5 or 13 weeks after the second injection were protected from viral replication in the lungs and nose. Importantly, mice challenged 7 weeks after only a single dose of 1 mcg or 10 mcg of mRNA-1273 were also protected against viral replication in the lung.

The investigational vaccine also induced robust CD8 T-cell responses in mice. It did not induce the type of cellular immune response that has been linked to vaccine-associated enhanced respiratory disease (VAERD). This rare, allergic-type inflammation was seen in individuals vaccinated with a whole-inactivated respiratory syncytial virus (RSV) vaccine in the 1960s. VAERD can occur when a vaccine induces an immune response that is not strong enough to protect against infection. The investigators vaccinated mice with sub-protective doses of mRNA-1273 and then challenged the mice with SARS-CoV-2. The mice showed no evidence of enhanced lung pathology or excessive mucus production, indicating the vaccine did not cause enhanced disease, the authors write.



The authors note that the data from these studies, combined with data from studies in nonhuman primates and Phase 1 clinical testing, support the evaluation of mRNA-1273 in clinical efficacy trials.

They also explain how their prior research on a candidate MERS-CoV vaccine **paved the way for a rapid response to the COVID-19 outbreak.** "This is a demonstration of how the power of new technology-driven concepts like synthetic vaccinology facilitates a vaccine development program that can be initiated with pathogen sequences alone," the authors write. A media advisory describes a basic research finding. Basic research increases our understanding of human behavior and biology, which is foundational to advancing new and better ways to prevent, diagnose, and treat disease. Science is an unpredictable and incremental process — each research advance builds on past discoveries, often in unexpected ways. Most clinical advances would not be possible without the knowledge of fundamental basic research.

NIAID conducts and supports research — at NIH, throughout the United States, and worldwide — to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

National Institutes Of Health (NIH) And Moderna Announce Start Of Phase 3 Clinical Trial

The National Institutes of Health (NIH) and Moderna have announced that **they have started a Phase 3 clinical trial, called the COVE (Coronavirus Efficacy) study, for their investigational vaccine for coronavirus 2019 (COVID-19).**

The vaccine, known as mRNA-1273, was co-developed by NIH and Moderna. The trial will be conducted at US sites, and is expected to enroll approximately 30000 adults who do not have the virus.

"Results from early-stage clinical testing indicate the investigational mRNA-1273 vaccine is safe and immunogenic, supporting the initiation of a Phase 3 clinical trial," National Institute of Allergy and Infectious Diseases (NIAID) Director Anthony S. Fauci, MD said. "This scientifically rigorous, randomized, placebo-controlled trial is designed to determine if the vaccine can prevent COVID-19 and for how long such protection may last."

In a wide-ranging interview he gave last month, Fauci spoke about a number of COVID-19 issues including vaccines. The trial is designed to evaluate the safety of mRNA-1273 and to determine if the vaccine can prevent symptomatic COVID-19 after two doses. As secondary goals, the trial also aims to study whether the vaccine can prevent severe COVID-19 or laboratory-confirmed SARS-CoV-2 infection with or without disease symptoms. The trial also seeks to answer if the vaccine can prevent death caused by COVID-19 and whether just one dose can prevent symptomatic COVID-19, among other objectives.

Trial volunteers will receive two intramuscular injections approximately 28 days apart. Participants will be randomly assigned 1:1 to receive either two 100 microgram (mcg) injections of mRNA-1273 or two shots of a saline placebo. The trial is blinded, so the investigators and the participants will not know who is assigned to which group.

The vaccine efficacy trial is the first to be implemented under **Operation Warp Speed,** a multi-agency collaboration led by HHS that aims to accelerate the development, manufacturing and distribution of medical countermeasures for COVID-19.

A Phase 1 clinical trial found the candidate vaccine to be safe, generally well-tolerated, and able to induce antibodies with high levels of virus-neutralizing activity. Moderna initiated Phase 2 testing of the vaccine in May 2020.

AstraZeneca Starts Phase 3 Trial For Its COVID-19 Vaccine In The U.S.

AstraZeneca announced last Monday that it has entered a Phase 3 trial for its COVID-19 vaccine candidate, AZD1222, in the United States.

Trial centers across the US are recruiting up to 30,000 adult volunteers for the Phase 3 trials. Prospective participants must be at least 18 years or over, can be from diverse racial, ethnic, and geographic groups who are healthy or have stable underlying medical conditions, including those living with HIV, and who are at increased risk of infection from the SARS-CoV-2 virus.

Outside the US, the criteria for medical centers to be included are based on predicted transmission rates of the virus. Centers in Peru and Chile will be starting recruitment soon.

"We are pleased that AZD1222 demonstrated safety and immunogenicity across all adult age groups and are proud to be collaborating with BARDA and NIAID to accelerate the development of this vaccine. Should clinical trials demonstrate the vaccine protects against COVID-19 disease and is approved for use, we will work hard to make it globally available in a fair and equitable manner as rapidly as possible." Mene Pangalos, executive vice president, BioPharmaceuticals R&D, said.

Participants are being randomized to receive two doses of either AZD1222 or a saline control, 4 weeks apart, with twice as many participants receiving the potential vaccine than the saline control. The trial is assessing efficacy and safety of the vaccine in all participants, and local and systemic reactions and immune responses will be assessed in 30,000 participants. (Courtesy https://www.contagionlive.com/)

Southern DAILY Make Today Different

Editor's Choice

An Israeli soldier detains a Palestinian demonstrator during a protest against Jewish settlements in Jbarah village south of Tulkarm in the Israeli-occupied West Bank. REUTERS/Raneen Sawafta

An Israeli delegation led by National Security Advisor Meir Ben-Shabbat, and U.S. National Security Advisor Robert O'Brien and U.S. President Trump's senior adviser Jared Kushner board the Israeli flag carrier El Al's airliner as they fly to Abu Dhabi for talks meant to put final touches on the normalisation deal between the United Arab Emirates and Israel, at Ben Gurion International Airport, near Tel Aviv, Israel. REUTERS/Nir Elias

U.S. Democratic presidential nominee and former Vice President Joe Biden speaks about safety in a socially-distanced room of reporters in Pittsburgh, Pennsylvania. REUTERS/Alan Freed

A view shows the damage at Car Source, a used car lot on Sheridan Road over a week since Black man Jacob Blake was shot by police and a day before a visit by U.S. President Donald Trump in Kenosha, Wisconsin. REUTERS/Kamil Krzaczynski

Evacuees displaced by Hurricane Laura look through items that had been dropped off on the curb outside of the New Orleans Marriott in New Orleans, Louisiana. REUTERS/Kathleen Flynn

Angelique Kerber of Germany serves to Ajla Tomljanovic of Australia (not pictured) with tarps covering the lower seats reading, "New York Tough," and "Black Lives Matter," in the first round on day one of the 2020 U.S. Open tennis tournament

French President Emmanuel Macron hugs blast victim Tamara Tayah as he attends a ceremony to plant a cedar with members of the NGO Jouzour Loubnan in Jaj, near Beirut, Lebanon. REUTERS/Gonzalo Fuentes/Pool

Iraqi people collect recyclable garbage at a dump in the holy city of Najaf, Iraq. REUTERS/Alaa Al-Marjani

Southern DAILY Make Today Different

COMMUNITY

15-Minute Test For COVID-19 Has Just Been Approved



The portable test is about the size of a credit card. (Photo/Abbott Laboratories)

KEY POINTS

Abbott Laboratories has won approval for a COVID-19 portable antigen test that delivers results in 15 minutes and will sell for $5.

The portable coronavirus test is about the size of a credit card and requires no additional equipment to operate.

Compiled And Edited By John T. Robbins, Southern Daily Editor

bbott Laboratories said on Wednesday it won U.S. marketing authorization for a COVID-19 portable antigen test that can deliver results within 15 minutes and will sell for $5.

The portable test is about the size of a credit card, requires no additional equipment to operate, and can be conducted using a less invasive nasal swab than traditional lab tests, Abbott executives said on a call with reporters.

Abbott expects to ship tens of millions of tests in September, ramping to 50 million tests a month from the beginning of October.

The test, BinaxNOW COVID-19 Ag Card, could be used to check that people participating in larger gatherings, such as those returning to schools or workplaces, do not have COVID-19 and could help aid the reopening of the U.S., the executives said.

Abbott created a downloadable app that people who have taken the test could present before entering venues to show that they are COVID-19 free, they said.

Antigen tests are cheaper and faster than molecular diagnostic tests but somewhat more likely to fail to identify positive cases of the virus than lab-based diagnostic tests.

Abbott expects to ship tens of millions of tests in September.

Image: Abbott Laboratories

The U.S. Food and Drug Administration granted the approval under its emergency use authorization program. Becton Dickinson and Co and Quidel Corp already market antigen tests.

The United States now has more cases of the coronavirus than any other country at more than 5 million, and hospitals and labs have struggled to meet the demand to test thousands of people.

Since March, the company has got U.S. authorizations for five other coronavirus tests, including one called the ID Now that can deliver results within minutes and is used at the White House.

3 in 4 adults around the world say they would get a COVID-19 vaccine

Respondents from China were the most likely to say they'd get a vaccine once available. Image: REUTERS/Tingshu Wang

• New survey shows a majority of people would get a COVID-19 vaccine.

• But people are not optimistic that one is likely to be ready by the end of 2020.

• For those who wouldn't get the vaccine, concern about side effects was the most commonly cited reason.

A new Ipsos survey, conducted on behalf of the World Economic Forum, shows that three-quarters of adults would get a vaccine for COVID-19 if it were available.

But nearly two-thirds (59%) don't think one will be available by the end of 2020.

The study, which covers nearly 20,000 adults in 27 countries, also reveals where in the world take-up would be strongest.

Would you get a COVID-19 vaccine?

Of those surveyed, 74% strongly or somewhat agreed with the statement "if a vaccine for COVID-19 were available, I would get it".

In China, this figure rose to 97%, but was lowest in Russia, Poland and Hungary.

(Courtesy https://www.weforum.org/and reut.rs/2QsSyOC) (Courtesy https://www.weforum.org/agenda)